Recombinant Anti-Human CD20 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: B9E9) PA007456 Ushelf

Anti-Human CD20 Antibody (Clone: B9E9) | PA007456

$200.00 – $1,250.00

Recombinant Mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Details & Specifications
References

Catalog No.	PA007456
Product Name	In vivo Grade Recombinant Anti-Human CD20 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: B9E9)
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, CD antigen CD20, CD20
Clone	B9E9.
Isotype	Mouse IgG2a Kappa.
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: B9E9) specifically binds to mouse CD20.
Applications	ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD20 protein.
Form Of Antibody	0.2 μM filtered solution of 1x PBS.
Endotoxin	Less than 1 EU/mg of protein as determined by LAL method.
Purity	>95% by SDS-PAGE under reducing conditions.
Shipping	The in vivo grade recombinant anti-human CD20 antibodies (clone of B9E9) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant Mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007456: Recombinant Anti-Human CD20 Monoclonal Antibody (Clone: B9E9), Mouse IgG2a Kappa, In vivo Grade

The in vivo grade recombinant anti-human CD20 Mouse IgG2a Kappa monoclonal antibody was produced in mammalian cells.

References of Anti-Human CD20 Monoclonal Antibody (Clone: B9E9)

1. Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity.
Morita, D., et al. J Immunother Cancer. 2024 Dec 9;12(12):e009741. doi: 10.1136/jitc-2024-009741. PMID: 39653552
“Fluorochrome-conjugated monoclonal antibodies, including anti-human CD20 (clone B9E9), were used to stain human cells for flow cytometry analysis with Gallios or BD FACSymphony cytometers at Texas Children’s Hospital. Eight weeks post-injection, PBMCs from humanized mice were stained with anti-human CD45 to confirm humanization. Other antibodies, such as anti-CD3 (UCHT1), CD4 (SK3), and CD8 (RPA-T8), were used to assess immune cell profiles, demonstrating T-cell redirection for enhanced antitumor immunity.”

2. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Forero, A., et al. Blood. 2004 Jul 1;104(1):227-36. doi: 10.1182/blood-2003-09-3284. PMID: 14996706
“A phase 1 trial assessed the safety, pharmacokinetics, and immunogenicity of a tetrameric single-chain anti-CD20-streptavidin fusion protein (B9E9FP) in patients with B-cell non-Hodgkin lymphoma (NHL) for pretargeted radioimmunotherapy (PRIT). The B9E9FP (anti-human CD20) targeted HLA class I/peptide complexes, showing in vivo activity when combined with anti-viral T cells, supporting further clinical development with autologous CTLs from vaccination or ex vivo expansion.”

3. An oncolytic measles virus engineered to enter cells through the CD20 antigen.
Bucheit, A. D., et al. Mol Ther. 2003 Jan;7(1):62-72. doi: 10.1016/s1525-0016(02)00033-3. PMID: 12573619
“An oncolytic measles virus (MV) was engineered to enter CD20(+) target cells via a single-chain (scFv) anti-CD20 antibody (B9E9) interaction with the CD20 antigen in non-Hodgkin’s lymphoma (NHL) models. The virus demonstrated enhanced oncolytic activity in vivo against CD20(+) tumors, showing equivalent effects on CD20(-) tumors, highlighting the clinical relevance of B9E9 (anti-human CD20) for targeted viral therapy.”

4. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice.
Savage, P., et al. Int J Cancer. 2002 Apr 1;98(4):538-44. doi: 10.1002/ijc.10219. PMID: 11920616
“The B9E9 scFvSA fusion protein (anti-human CD20) targeted HLA-A2/M1 complexes to Daudi cells, enabling CTL-mediated killing in vitro at dilutions as low as 100 pg/ml. In vivo SCID mouse assays showed that only one of four mice receiving B9E9 scFvSA, HLA-A2/M1 complexes, and anti-HLA-A2/M1 CTLs developed a tumor, supporting clinical development with autologous CTLs.”

5. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes.
Savage, P., et al. Br J Cancer. 2002 Apr 22;86(8):1336-42. doi: 10.1038/sj.bjc.6600223. PMID: 11953895
“The B9E9 scFvSA fusion protein (anti-human CD20 mAb) delivered HLA-A2/class I peptide complexes to HLA class I-negative Daudi cells. Flow cytometry confirmed retention of targeted HLA-A2/M1 complexes, and in vitro CTL responses were observed in PBMCs pre-treated with B9E9 scFvSA. The B9E9 fusion protein, currently in clinical trials for B-cell lymphoma with radiolabeled biotin, demonstrated effective targeting for CTL induction.”

Syd Labs provides the following recombinant anti-human CD20 monoclonal antibodies:
Recombinant anti-human CD20 antibodies (clone 2H7), In vivo grade
Recombinant anti-human CD20 antibodies (clone B9E9), In vivo grade

Anti-Human CD20 (B9E9) from: Anti-Human CD20 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: B9E9): PA007456 Syd Labs